Citations

Clear

16281 citation(s) found for "Yu, David".

Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states
Karpyak, Victor M. , Winham, Stacey J. , Preuss, Ulrich W. , Zill, Peter , Cunningham, Julie M. , Walker, Denise L., Lewis, Kriste A., Geske, Jennifer R. , Colby, Colin , Hall‐Flavin, Daniel K., Loukianova, Larissa L., Schneekloth, Terry D. , Frye, Mark A. , Bazov, Igor , Heit, John A. , Bakalkin, Georgy , Mrazek, David A. , Abulseoud, Osama A. , Biernacka, Joanna M. , Winham, Stacey J , Karpyak, Victor , Bakalkin, Georgy , Geske, Jennifer

Mayo Clinic

International Journal of Neuropsychopharmacology | October 29, 2012 | Volume: 16 | Issue: 5 | Pages: 975-985

10.1017/s1461145712001137 | PMID 23101464 Get It

AbstractSynthetic κ-opioid receptor (KOR) agonists induce dysphoric and pro-depressive effects and variations in the KOR (OPRK1) and prodynorphin (PDYN) genes have been shown to be associated with alcohol dependence. We genotyped 23 single nucleotide polymorphisms (SNPs) in the PDYN and OPRK1 genes in 816 alcohol-dependent subjects and investigated their association with: (1) negative craving measured by a subscale of the Inventory of Drug Taking Situations; (2) a self-reported history of depression; (3) the intensity of depressive symptoms measured by the Beck Depression Inventory-II. In addition, 13 of the 23 PDYN and OPRK1 SNPs, which were previously genotyped in a set of 1248 controls, were used to evaluate association with alcohol dependence. SNP and haplotype tests of association were performed. Analysis of a haplotype spanning the PDYN gene (rs6045784, rs910080, rs2235751, rs2281285) revealed significant association with alcohol dependence (p = 0.00079) and with negative craving (p = 0.0499). A candidate haplotype containing the PDYN rs2281285-rs1997794 SNPs that was previously associated with alcohol dependence was also associated with negative craving (p = 0.024) and alcohol dependence (p = 0.0008) in this study. A trend for association between depression severity and PDYN variation was detected. No associations of OPRK1 gene variation with alcohol dependence or other studied phenotypes were found. These findings support the hypothesis that sequence variation in the PDYN gene contributes to both alcohol dependence and the induction of negative craving in alcohol-dependent subjects.
Standardization of analysis sets for reporting results from ADNI MRI data
Wyman, Bradley T., Harvey, Danielle , Crawford, Karen , Carmichael, Owen , Cole, Patricia E., Crane, Paul K. , DeCarli, Charles , Fox, Nick C. , Gunter, Jeffrey L. , Hill, David , Killiany, Ronald , Pachaï, Chahin , Schwarz, Adam J. , Schuff, Norbert, Senjem, Matthew L. , Suhy, Joyce, Thompson, Paul M. , Weiner, Michael W. , Initiative, Alzheimer's Disease Neuroimaging, Hsiung, Ging‐Yuek Robin , Preda, Adrian , Jicha, Gregory A. , Ponto, Laura L. Boles , Bernstein, Matt A. , Jack, Clifford R. , Initiative, Alzheimer's Disease Neuroimaging, DeCarli, Charles , Preda, Adrian , Thompson, Paul M , Hsiung, Gink-Yuek , Senjem, Matthew L , Fox, Nick C , Harvey, Danielle J , Jicha, Gregory A

Mayo Clinic

Alzheimer's & Dementia | October 27, 2012 | Volume: 9 | Issue: 3 | Pages: 332-337

10.1016/j.jalz.2012.06.004 | PMID 23110865 Get It

AbstractThe Alzheimer's Disease Neuroimaging Initiative (ADNI) three‐dimensional T1‐weighted magnetic resonance imaging (MRI) acquisitions provide a rich data set for developing and testing analysis techniques for extracting structural endpoints. To promote greater rigor in analysis and meaningful comparison of different algorithms, the ADNI MRI Core has created standardized analysis sets of data comprising scans that met minimum quality control requirements. We encourage researchers to test and report their techniques against these data. Standard analysis sets of volumetric scans from ADNI‐1 have been created, comprising screening visits, 1‐year completers (subjects who all have screening, 6‐ and 12‐month scans), 2‐year annual completers (screening, 1‐year and 2‐year scans), 2‐year completers (screening, 6‐months, 1‐year, 18‐months [mild cognitive impaired (MCI) only], and 2‐year scans), and complete visits (screening, 6‐month, 1‐year, 18‐month [MCI only], 2‐year, and 3‐year [normal and MCI only] scans). As the ADNI‐GO/ADNI‐2 data become available, updated standard analysis sets will be posted regularly.
Teleconcussion: An Innovative Approach to Screening, Diagnosis, and Management of Mild Traumatic Brain Injury
Vargas, Bert B., Channer, Dwight D., Dodick, David W. , Demaerschalk, Bart M.

Mayo Clinic

Telemedicine and e-Health | October 26, 2012 | Volume: 18 | Issue: 10 | Pages: 803-806

10.1089/tmj.2012.0118 | PMID 23101482 Get It

Concussion awareness and management in sports have gained a great deal of attention in light of research illustrating the potentially devastating consequences of repeated traumatic brain injuries. In order to address this public health crisis, numerous states have passed legislation that mandates medical clearance before being eligible to return to play of concussed athletes by a qualified healthcare provider. As the number of qualified healthcare providers with expertise in the diagnosis and management of concussions remains very small, patient safety and the ability to fulfill these legislative return-to-play requirements present unique problems to rural communities without easy access to subspecialty care. Telemedicine is a possible means by which to address the needs of the rural student-athlete.
Robotic Intracorporeal Urinary Diversion: Ileal Conduit
Johnson, David C. , Castle, Erik P., Pruthi, Raj S. , Woods, Michael E.

Mayo Clinic

Journal of Endourology | October 26, 2012 | Volume: 26 | Issue: 12 | Pages: 1566-1569

10.1089/end.2012.0447 | PMID 23102129 Get It

Resolution of Acute Onset Hemichorea–Hemiballismus After Treatment With Intravenous Tissue Plasminogen Activator
McCollum, David , Silvers, Scott M., Barrett, Kevin M. , Dawson, Stephanie

Mayo Clinic

The Neurohospitalist | October 26, 2012 | Volume: 3 | Issue: 3 | Pages: 131-134

10.1177/1941874412464055 | PMID 24167646 Get It

Hyperkinetic movement disorders are uncommon after acute ischemic stroke. Since these movement disorders are rarely the initial manifestation of acute cerebral ischemia, their presence may result in diagnostic uncertainty or it may inappropriately delay intravenous thrombolytic therapy for ischemic stroke. Hemichorea–hemiballism (HC-HB) is one of the more frequently encountered hyperkinetic movement disorders occurring in conjunction with stroke. Although HC-HB may result from a stroke mimic, the acute onset should prompt rapid evaluation and consideration for the presence of stroke along with its time-dependent therapies including recombinant tissue plasminogen activator (rtPA). In this article, we describe a case of a patient with acute cerebral ischemia presenting clinically with HC-HB, who was given intravenous rtPA therapy despite an initially negative, early diffusion-weighted magnetic resonance imaging (MRI). Follow-up brain MRI performed 24 hours after the initiation of thrombolytic therapy confirmed acute infarction in the contralateral striatum. The patient had near-complete resolution of her HC-HB on discharge and had no complications related to the administration of intravenous rtPA.
Lowering Kilovoltage to Reduce Radiation Dose in Contrast-Enhanced Abdominal CT: Initial Assessment of a Prototype Automated Kilovoltage Selection Tool
Hough, David M., Grant, Katharine L., Fidler, Jeff L. , Yu, Lifeng , Geske, Jennifer R. , Carter, Rickey E. , Raupach, Rainer , Schmidt, Bernhard , Flohr, Thomas , Fletcher, Joel G. , Fidler, Jeff L. , Yu, Lifeng , McCollough, Cynthia H. , Carter, Rickey E , Geske, Jennifer

Mayo Clinic

American Journal of Roentgenology | October 24, 2012 | Volume: 199 | Issue: 5 | Pages: 1070-1077

10.2214/ajr.12.8637 | PMID 23096181 Get It

Patient Satisfaction in an Academic Chronic Pain Clinic
Trentman, Terrence L. , Cornidez, Eric, Wilshusen, Laurie , Seamans, David P. , Rosenfeld, David M. , Freeman, John A., Chien, James J., Chang, Yu‐Hui

Mayo Clinic

Pain Practice | October 24, 2012 | Volume: 13 | Issue: 5 | Pages: 372-379

10.1111/papr.12004 | PMID 23094675 Get It

AbstractObjectivesPatient perception of healthcare quality is of growing interest. It has been shown that patient satisfaction is associated with compliance with medical advice and clinical outcome. The 3‐fold purpose of this study was to identify which attributes of the patient–physician interaction most strongly correlated with patients' perceptions of provider quality of care, to identify key drivers that move patients' perception of overall provider quality from “very good” to “excellent,” and to identify features of the pain clinic experience that were most important to patients but were simultaneously perceived as lacking.MethodsRandomized patient satisfaction survey conducted via telephone approximately 3 weeks after the patient's pain clinic visit.ResultsA total of 999 patients participated in the survey over 5 years (estimated response rate 60.2%). Thoroughness, listening, and time spent with the provider were the 3 attributes most strongly associated with the patients' perceptions of provider quality of care, while thoroughness, listening, punctuality, and clear instructions were the drivers of “very good” vs. “excellent” patient perceived overall provider quality. Areas identified for clinic improvement include thoroughness, providing adequate explanations and instructions, and including patient preferences in decision making.ConclusionsThese results may guide pain clinic physicians as they seek to improve patient perceptions of their care and ultimately patient outcomes.
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Karp, Judith E. , Thomas, B M , Greer, Jacqueline M., Sorge, Christopher L., Gore, Steven D. , Pratz, Keith W. , Flatten, Karen S., Peterson, Kevin, Schneider, Paula A., Mackey, Karen, Freshwater, Tomoko, McDevitt, Michael A. , Gladstone, Douglas E. , Showel, Margaret M. , Loechner, Sabine, Horowitz, Jo Ann, Isaacs, Randi , Smith, B. Douglas , Levis, Mark J. , Carraway, Hetty E. , Parry, David , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | October 24, 2012 | Volume: 18 | Issue: 24 | Pages: 6723-6731

10.1158/1078-0432.ccr-12-2442 | PMID 23092873 Get It

Abstract Purpose: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine cytotoxicity in acute leukemia cell lines and leukemic blasts in vitro. To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776. Experimental Design: Twenty-four adults with relapsed and refractory acute leukemias received timed sequential, continuous infusion cytarabine 2 g/m2 over 72 hours (667 mg/m2/24 hours) beginning on day 1 and again on day 10. SCH 900776 was administered as a 15- to 30-minute infusion on days 2, 3, 11, and 12. The starting dose of SCH 900776 was 10 mg/m2/dose. Results: Dose-limiting toxicities consisting of corrected QT interval prolongation and grade 3 palmar-plantar erythrodysesthesia occurred at 140 mg flat dosing (dose level 5, equivalent to 80 mg/m2). Complete remissions occurred in 8 of 24 (33%) patients, with 7 of 8 at 40 mg/m2 or higher. SCH 900776 did not accumulate at any dose level. Marrow blasts obtained pretreatment and during therapy showed increased phosphorylation of H2Ax after SCH 900776 beginning at 40 mg/m2, consistent with unrepaired DNA damage. Conclusions: These data support a randomized phase II trial of cytarabine +/− SCH 900776 at a recommended flat dose of 100 mg (equivalent to 56 mg/m2) for adults with poor-risk leukemias. The trial (SP P05247) was registered at www.clinicaltrials.gov as NCT00907517. Clin Cancer Res; 18(24); 6723–31. ©2012 AACR.